Seaport Therapeutics Announces First Patient Dosed In Phase 2a Trial Of GlyphAgo In Generalized Anxiety Disorder, Expects Topline Data In Early 2028
Share
Why It Matters
Seaport started testing a new anxiety medicine on real patients. Watch for results in early 2028 to see if it actually works.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.